Table of Content

1 Report Overview
1.1 Anti-Cancer Drug Definition
1.2 Market by Type
1.2.1 Global Anti-Cancer Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034
1.2.2 Avastin
1.2.3 Rituxan
1.2.4 Herceptin
1.2.5 Alimta
1.3 Market Segment by Application
1.3.1 Global Anti-Cancer Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Home Care
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Anti-Cancer Drug Sales
2.1 Global Anti-Cancer Drug Revenue Estimates and Forecasts 2018-2034
2.2 Global Anti-Cancer Drug Revenue by Region: 2018 VS 2024 VS 2034
2.3 Global Anti-Cancer Drug Revenue by Region
2.3.1 Global Anti-Cancer Drug Revenue by Region (2018-2023)
2.3.2 Global Anti-Cancer Drug Revenue by Region (2024-2034)
2.4 Global Anti-Cancer Drug Sales Quantity Estimates and Forecasts 2018-2034
2.5 Global Anti-Cancer Drug Sales Quantity by Region: 2018 VS 2024 VS 2034
2.6 Global Anti-Cancer Drug Sales Quantity by Region
2.6.1 Global Anti-Cancer Drug Sales Quantity by Region (2018-2023)
2.6.2 Global Anti-Cancer Drug Sales Quantity by Region (2024-2034)
2.7 North America
2.8 Europe
2.9 China
2.10 APAC (excluding China)
2.11 Middle East, Africa and Latin America
3 Competition by Manufacturers
3.1 Global Anti-Cancer Drug Sales Quantity by Manufacturers
3.1.1 Global Anti-Cancer Drug Sales Quantity by Manufacturers (2018-2023)
3.1.2 Global Anti-Cancer Drug Sales Quantity Share by Manufacturers (2018-2023)
3.1.3 Global Top 10 and Top 5 Companies by Anti-Cancer Drug Sales in 2024
3.2 Global Anti-Cancer Drug Revenue by Manufacturers
3.2.1 Global Anti-Cancer Drug Revenue by Manufacturers (2018-2023)
3.2.2 Global Anti-Cancer Drug Revenue Share by Manufacturers (2018-2023)
3.2.3 Global Top 10 and Top 5 Companies by Anti-Cancer Drug Revenue in 2024
3.3 Global Anti-Cancer Drug Sales Price by Manufacturers
3.4 Global Key Players of Anti-Cancer Drug, Industry Ranking, 2021 VS 2024
3.5 Analysis of Competitive Landscape
3.5.1 Manufacturers Market Concentration Ratio (CR5 and HHI)
3.5.2 Global Anti-Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.6 Global Key Manufacturers of Anti-Cancer Drug, Manufacturing Base Distribution and Headquarters
3.7 Global Key Manufacturers of Anti-Cancer Drug, Product Offered and Application
3.8 Global Key Manufacturers of Anti-Cancer Drug, Date of Enter into This Industry
3.9 Mergers & Acquisitions, Expansion Plans
4 Estimates and Forecasts by Type
4.1 Global Anti-Cancer Drug Sales Quantity by Type
4.1.1 Global Anti-Cancer Drug Historical Sales Quantity by Type (2018-2023)
4.1.2 Global Anti-Cancer Drug Forecasted Sales Quantity by Type (2024-2034)
4.1.3 Global Anti-Cancer Drug Sales Quantity Market Share by Type (2018-2034)
4.2 Global Anti-Cancer Drug Revenue by Type
4.2.1 Global Anti-Cancer Drug Historical Revenue by Type (2018-2023)
4.2.2 Global Anti-Cancer Drug Forecasted Revenue by Type (2024-2034)
4.2.3 Global Anti-Cancer Drug Revenue Market Share by Type (2018-2034)
4.3 Global Anti-Cancer Drug Price by Type
4.3.1 Global Anti-Cancer Drug Price by Type (2018-2023)
4.3.2 Global Anti-Cancer Drug Price Forecast by Type (2024-2034)
5 Market Size by Application
5.1 Global Anti-Cancer Drug Sales Quantity by Application
5.1.1 Global Anti-Cancer Drug Historical Sales Quantity by Application (2018-2023)
5.1.2 Global Anti-Cancer Drug Forecasted Sales Quantity by Application (2024-2034)
5.1.3 Global Anti-Cancer Drug Sales Quantity Market Share by Application (2018-2034)
5.2 Global Anti-Cancer Drug Revenue by Application
5.2.1 Global Anti-Cancer Drug Historical Revenue by Application (2018-2023)
5.2.2 Global Anti-Cancer Drug Forecasted Revenue by Application (2024-2034)
5.2.3 Global Anti-Cancer Drug Revenue Market Share by Application (2018-2034)
5.3 Global Anti-Cancer Drug Price by Application
5.3.1 Global Anti-Cancer Drug Price by Application (2018-2023)
5.3.2 Global Anti-Cancer Drug Price Forecast by Application (2024-2034)
6 North America
6.1 North America Anti-Cancer Drug Sales by Company
6.1.1 North America Anti-Cancer Drug Revenue by Company (2018-2023)
6.1.2 North America Anti-Cancer Drug Sales Quantity by Company (2018-2023)
6.2 North America Anti-Cancer Drug Market Size by Type
6.2.1 North America Anti-Cancer Drug Sales Quantity by Type (2018-2034)
6.2.2 North America Anti-Cancer Drug Revenue by Type (2018-2034)
6.3 North America Anti-Cancer Drug Market Size by Application
6.3.1 North America Anti-Cancer Drug Sales Quantity by Application (2018-2034)
6.3.2 North America Anti-Cancer Drug Revenue by Application (2018-2034)
6.4 North America Anti-Cancer Drug Market Size by Country
6.4.1 North America Anti-Cancer Drug Revenue by Country: 2018 VS 2024 VS 2034
6.4.2 North America Anti-Cancer Drug Revenue by Country (2018-2034)
6.4.3 North America Anti-Cancer Drug Sales Quantity by Country (2018-2034)
6.4.4 U.S.
6.4.5 Canada
7 Europe
7.1 Europe Anti-Cancer Drug Sales by Company
7.1.1 Europe Anti-Cancer Drug Sales Quantity by Company (2018-2023)
7.1.2 Europe Anti-Cancer Drug Revenue by Company (2018-2023)
7.2 Europe Anti-Cancer Drug Market Size by Type
7.2.1 Europe Anti-Cancer Drug Sales Quantity by Type (2018-2034)
7.2.2 Europe Anti-Cancer Drug Revenue by Type (2018-2034)
7.3 Europe Anti-Cancer Drug Market Size by Application
7.3.1 Europe Anti-Cancer Drug Sales Quantity by Application (2018-2034)
7.3.2 Europe Anti-Cancer Drug Revenue by Application (2018-2034)
7.4 Europe Anti-Cancer Drug Market Size by Country
7.4.1 Europe Anti-Cancer Drug Revenue by Country: 2018 VS 2024 VS 2034
7.4.2 Europe Anti-Cancer Drug Revenue by Country (2018-2034)
7.4.3 Europe Anti-Cancer Drug Sales Quantity by Country (2018-2034)
7.4.4 Germany
7.4.5 France
7.4.6 U.K.
7.4.7 Italy
7.4.8 Russia
8 China
8.1 China Anti-Cancer Drug Sales by Company
8.1.1 China Anti-Cancer Drug Sales Quantity by Company (2018-2023)
8.1.2 China Anti-Cancer Drug Revenue by Company (2018-2023)
8.2 China Anti-Cancer Drug Market Size by Type
8.2.1 China Anti-Cancer Drug Sales Quantity by Type (2018-2034)
8.2.2 China Anti-Cancer Drug Revenue by Type (2018-2034)
8.3 China Anti-Cancer Drug Market Size by Application
8.3.1 China Anti-Cancer Drug Sales Quantity by Application (2018-2034)
8.3.2 China Anti-Cancer Drug Revenue by Application (2018-2034)
9 APAC (excluding China)
9.1 APAC Anti-Cancer Drug Sales by Company
9.1.1 APAC Anti-Cancer Drug Sales Quantity by Company (2018-2023)
9.1.2 APAC Anti-Cancer Drug Revenue by Company (2018-2023)
9.2 APAC Anti-Cancer Drug Market Size by Type
9.2.1 APAC Anti-Cancer Drug Sales Quantity by Type (2018-2034)
9.2.2 APAC Anti-Cancer Drug Revenue by Type (2018-2034)
9.3 APAC Anti-Cancer Drug Market Size by Application
9.3.1 APAC Anti-Cancer Drug Sales Quantity by Application (2018-2034)
9.3.2 APAC Anti-Cancer Drug Revenue by Application (2018-2034)
9.4 APAC Anti-Cancer Drug Market Size by Region
9.4.1 APAC Anti-Cancer Drug Revenue by Region: 2018 VS 2024 VS 2034
9.4.2 APAC Anti-Cancer Drug Revenue by Region (2018-2034)
9.4.3 APAC Anti-Cancer Drug Sales Quantity by Region (2018-2034)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
10 Middle East, Africa and Latin America
10.1 Middle East, Africa and Latin America Anti-Cancer Drug Sales by Company
10.1.1 Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Company (2018-2023)
10.1.2 Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Company (2018-2023)
10.2 Middle East, Africa and Latin America Anti-Cancer Drug Market Size by Type
10.2.1 Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Type (2018-2034)
10.2.2 Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Type (2018-2034)
10.3 Middle East, Africa and Latin America Anti-Cancer Drug Market Size by Application
10.3.1 Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Application (2018-2034)
10.3.2 Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Application (2018-2034)
10.4 Middle East, Africa and Latin America Anti-Cancer Drug Market Size by Country
10.4.1 Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Country: 2018 VS 2024 VS 2034
10.4.2 Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Country (2018-2034)
10.4.3 Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Country (2018-2034)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Israel
10.4.8 GCC Countries
11 Company Profiles
11.1 Merck
11.1.1 Merck Company Information
11.1.2 Merck Overview
11.1.3 Merck Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.1.4 Merck Anti-Cancer Drug Products and Services
11.1.5 Merck Anti-Cancer Drug SWOT Analysis
11.1.6 Merck Recent Developments
11.2 Bristol-Myers Squibb
11.2.1 Bristol-Myers Squibb Company Information
11.2.2 Bristol-Myers Squibb Overview
11.2.3 Bristol-Myers Squibb Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.2.4 Bristol-Myers Squibb Anti-Cancer Drug Products and Services
11.2.5 Bristol-Myers Squibb Anti-Cancer Drug SWOT Analysis
11.2.6 Bristol-Myers Squibb Recent Developments
11.3 Bayer
11.3.1 Bayer Company Information
11.3.2 Bayer Overview
11.3.3 Bayer Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.3.4 Bayer Anti-Cancer Drug Products and Services
11.3.5 Bayer Anti-Cancer Drug SWOT Analysis
11.3.6 Bayer Recent Developments
11.4 GlaxoSmithKline
11.4.1 GlaxoSmithKline Company Information
11.4.2 GlaxoSmithKline Overview
11.4.3 GlaxoSmithKline Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.4.4 GlaxoSmithKline Anti-Cancer Drug Products and Services
11.4.5 GlaxoSmithKline Anti-Cancer Drug SWOT Analysis
11.4.6 GlaxoSmithKline Recent Developments
11.5 Novartis
11.5.1 Novartis Company Information
11.5.2 Novartis Overview
11.5.3 Novartis Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.5.4 Novartis Anti-Cancer Drug Products and Services
11.5.5 Novartis Anti-Cancer Drug SWOT Analysis
11.5.6 Novartis Recent Developments
11.6 Sanofi
11.6.1 Sanofi Company Information
11.6.2 Sanofi Overview
11.6.3 Sanofi Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.6.4 Sanofi Anti-Cancer Drug Products and Services
11.6.5 Sanofi Anti-Cancer Drug SWOT Analysis
11.6.6 Sanofi Recent Developments
11.7 Pfizer
11.7.1 Pfizer Company Information
11.7.2 Pfizer Overview
11.7.3 Pfizer Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.7.4 Pfizer Anti-Cancer Drug Products and Services
11.7.5 Pfizer Anti-Cancer Drug SWOT Analysis
11.7.6 Pfizer Recent Developments
11.8 Amgen
11.8.1 Amgen Company Information
11.8.2 Amgen Overview
11.8.3 Amgen Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.8.4 Amgen Anti-Cancer Drug Products and Services
11.8.5 Amgen Anti-Cancer Drug SWOT Analysis
11.8.6 Amgen Recent Developments
11.9 Celgene Corporation
11.9.1 Celgene Corporation Company Information
11.9.2 Celgene Corporation Overview
11.9.3 Celgene Corporation Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.9.4 Celgene Corporation Anti-Cancer Drug Products and Services
11.9.5 Celgene Corporation Anti-Cancer Drug SWOT Analysis
11.9.6 Celgene Corporation Recent Developments
11.10 Ariad Pharmaceuticals
11.10.1 Ariad Pharmaceuticals Company Information
11.10.2 Ariad Pharmaceuticals Overview
11.10.3 Ariad Pharmaceuticals Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.10.4 Ariad Pharmaceuticals Anti-Cancer Drug Products and Services
11.10.5 Ariad Pharmaceuticals Anti-Cancer Drug SWOT Analysis
11.10.6 Ariad Pharmaceuticals Recent Developments
11.11 Eli Lilly
11.11.1 Eli Lilly Company Information
11.11.2 Eli Lilly Overview
11.11.3 Eli Lilly Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.11.4 Eli Lilly Anti-Cancer Drug Products and Services
11.11.5 Eli Lilly Recent Developments
11.12 Hoffmann-La Roche Ltd.
11.12.1 Hoffmann-La Roche Ltd. Company Information
11.12.2 Hoffmann-La Roche Ltd. Overview
11.12.3 Hoffmann-La Roche Ltd. Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.12.4 Hoffmann-La Roche Ltd. Anti-Cancer Drug Products and Services
11.12.5 Hoffmann-La Roche Ltd. Recent Developments
11.13 AstraZeneca
11.13.1 AstraZeneca Company Information
11.13.2 AstraZeneca Overview
11.13.3 AstraZeneca Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.13.4 AstraZeneca Anti-Cancer Drug Products and Services
11.13.5 AstraZeneca Recent Developments
11.14 Boehringer Ingelheim GmbH
11.14.1 Boehringer Ingelheim GmbH Company Information
11.14.2 Boehringer Ingelheim GmbH Overview
11.14.3 Boehringer Ingelheim GmbH Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.14.4 Boehringer Ingelheim GmbH Anti-Cancer Drug Products and Services
11.14.5 Boehringer Ingelheim GmbH Recent Developments
11.15 Teva Pharmaceuticals
11.15.1 Teva Pharmaceuticals Company Information
11.15.2 Teva Pharmaceuticals Overview
11.15.3 Teva Pharmaceuticals Anti-Cancer Drug Sales Quantity, Revenue, Average Selling Price (ASP) and Gross Margin (2018-2023)
11.15.4 Teva Pharmaceuticals Anti-Cancer Drug Products and Services
11.15.5 Teva Pharmaceuticals Recent Developments
12 Value Chain and Sales Channels Analysis
12.1 Anti-Cancer Drug Value Chain Analysis
12.2 Anti-Cancer Drug Key Raw Materials
12.2.1 Key Raw Materials
12.2.2 Raw Materials Key Suppliers
12.3 Anti-Cancer Drug Production Mode & Process
12.4 Anti-Cancer Drug Sales and Marketing
12.4.1 Anti-Cancer Drug Sales Channels
12.4.2 Anti-Cancer Drug Distributors
12.5 Anti-Cancer Drug Customers
13 Market Dynamics
13.1 Anti-Cancer Drug Industry Trends
13.2 Anti-Cancer Drug Market Drivers
13.3 Anti-Cancer Drug Market Challenges
13.4 Anti-Cancer Drug Market Restraints
14 Key Findings
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

List of Figure

List of Tables
Table 1. Global Anti-Cancer Drug Market Size Growth Rate (CAGR) by Type, 2018 VS 2024 VS 2034 (US$ Million)
Table 2. Major Manufacturers of Avastin
Table 3. Major Manufacturers of Rituxan
Table 4. Major Manufacturers of Herceptin
Table 5. Major Manufacturers of Alimta
Table 6. Global Anti-Cancer Drug Market Size Growth Rate (CAGR) by Application, 2018 VS 2024 VS 2034 (US$ Million)
Table 7. Global Anti-Cancer Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 8. Global Anti-Cancer Drug Revenue by Region (2018-2023) & (US$ Million)
Table 9. Global Anti-Cancer Drug Revenue Market Share by Region (2018-2023)
Table 10. Global Anti-Cancer Drug Revenue by Region (2024-2034) & (US$ Million)
Table 11. Global Anti-Cancer Drug Revenue Market Share by Region (2024-2034)
Table 12. Global Anti-Cancer Drug Sales Quantity by Region: 2018 VS 2024 VS 2034 (K Units)
Table 13. Global Anti-Cancer Drug Sales by Region (2018-2023) & (K Units)
Table 14. Global Anti-Cancer Drug Sales Market Share by Region (2018-2023)
Table 15. Global Anti-Cancer Drug Sales by Region (2024-2034) & (K Units)
Table 16. Global Anti-Cancer Drug Sales Market Share by Region (2024-2034)
Table 17. Global Anti-Cancer Drug Sales Quantity by Manufacturers (2018-2023) & (K Units)
Table 18. Global Anti-Cancer Drug Sales Quantity Share by Manufacturers (2018-2023)
Table 19. Global Anti-Cancer Drug Revenue by Manufacturers (2018-2023) & (US$ Million)
Table 20. Global Anti-Cancer Drug Revenue Share by Manufacturers (2018-2023)
Table 21. Global Anti-Cancer Drug Price by Manufacturers 2018-2023 (USD/Unit)
Table 22. Global Key Players of Anti-Cancer Drug, Industry Ranking, 2021 VS 2024
Table 23. Global Anti-Cancer Drug Manufacturers Market Concentration Ratio (CR5 and HHI)
Table 24. Global Anti-Cancer Drug by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Anti-Cancer Drug as of 2024)
Table 25. Global Key Manufacturers of Anti-Cancer Drug, Manufacturing Base Distribution and Headquarters
Table 26. Global Key Manufacturers of Anti-Cancer Drug, Product Offered and Application
Table 27. Global Key Manufacturers of Anti-Cancer Drug, Date of Enter into This Industry
Table 28. Mergers & Acquisitions, Expansion Plans
Table 29. Global Anti-Cancer Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 30. Global Anti-Cancer Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 31. Global Anti-Cancer Drug Sales Quantity Share by Type (2018-2023)
Table 32. Global Anti-Cancer Drug Sales Quantity Share by Type (2024-2034)
Table 33. Global Anti-Cancer Drug Revenue by Type (2018-2023) & (US$ Million)
Table 34. Global Anti-Cancer Drug Revenue by Type (2024-2034) & (US$ Million)
Table 35. Global Anti-Cancer Drug Revenue Share by Type (2018-2023)
Table 36. Global Anti-Cancer Drug Revenue Share by Type (2024-2034)
Table 37. Anti-Cancer Drug Price by Type (2018-2023) & (USD/Unit)
Table 38. Global Anti-Cancer Drug Price Forecast by Type (2024-2034) & (USD/Unit)
Table 39. Global Anti-Cancer Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 40. Global Anti-Cancer Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 41. Global Anti-Cancer Drug Sales Quantity Share by Application (2018-2023)
Table 42. Global Anti-Cancer Drug Sales Quantity Share by Application (2024-2034)
Table 43. Global Anti-Cancer Drug Revenue by Application (2018-2023) & (US$ Million)
Table 44. Global Anti-Cancer Drug Revenue by Application (2024-2034) & (US$ Million)
Table 45. Global Anti-Cancer Drug Revenue Share by Application (2018-2023)
Table 46. Global Anti-Cancer Drug Revenue Share by Application (2024-2034)
Table 47. Anti-Cancer Drug Price by Application (2018-2023) & (USD/Unit)
Table 48. Global Anti-Cancer Drug Price Forecast by Application (2024-2034) & (USD/Unit)
Table 49. North America Anti-Cancer Drug Revenue by Company (2018-2023) & (US$ Million)
Table 50. North America Anti-Cancer Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 51. North America Anti-Cancer Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 52. North America Anti-Cancer Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 53. North America Anti-Cancer Drug Revenue by Type (2018-2023) & (US$ Million)
Table 54. North America Anti-Cancer Drug Revenue by Type (2024-2034) & (US$ Million)
Table 55. North America Anti-Cancer Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 56. North America Anti-Cancer Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 57. North America Anti-Cancer Drug Revenue by Application (2018-2023) & (US$ Million)
Table 58. North America Anti-Cancer Drug Revenue by Application (2024-2034) & (US$ Million)
Table 59. North America Anti-Cancer Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 60. North America Anti-Cancer Drug Revenue by Country (2018-2023) & (US$ Million)
Table 61. North America Anti-Cancer Drug Revenue by Country (2024-2034) & (US$ Million)
Table 62. North America Anti-Cancer Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 63. North America Anti-Cancer Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 64. Europe Anti-Cancer Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 65. Europe Anti-Cancer Drug Revenue by Company (2018-2023) & (US$ Million)
Table 66. Europe Anti-Cancer Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 67. Europe Anti-Cancer Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 68. Europe Anti-Cancer Drug Revenue by Type (2018-2023) & (US$ Million)
Table 69. Europe Anti-Cancer Drug Revenue by Type (2024-2034) & (US$ Million)
Table 70. Europe Anti-Cancer Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 71. Europe Anti-Cancer Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 72. Europe Anti-Cancer Drug Revenue by Application (2018-2023) & (US$ Million)
Table 73. Europe Anti-Cancer Drug Revenue by Application (2024-2034) & (US$ Million)
Table 74. Europe Anti-Cancer Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 75. Europe Anti-Cancer Drug Revenue by Country (2018-2023) & (US$ Million)
Table 76. Europe Anti-Cancer Drug Revenue by Country (2024-2034) & (US$ Million)
Table 77. Europe Anti-Cancer Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 78. Europe Anti-Cancer Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 79. China Anti-Cancer Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 80. China Anti-Cancer Drug Revenue by Company (2018-2023) & (US$ Million)
Table 81. China Anti-Cancer Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 82. China Anti-Cancer Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 83. China Anti-Cancer Drug Revenue by Type (2018-2023) & (US$ Million)
Table 84. China Anti-Cancer Drug Revenue by Type (2024-2034) & (US$ Million)
Table 85. China Anti-Cancer Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 86. China Anti-Cancer Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 87. China Anti-Cancer Drug Revenue by Application (2018-2023) & (US$ Million)
Table 88. China Anti-Cancer Drug Revenue by Application (2024-2034) & (US$ Million)
Table 89. APAC Anti-Cancer Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 90. APAC Anti-Cancer Drug Revenue by Company (2018-2023) & (US$ Million)
Table 91. APAC Anti-Cancer Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 92. APAC Anti-Cancer Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 93. APAC Anti-Cancer Drug Revenue by Type (2018-2023) & (US$ Million)
Table 94. APAC Anti-Cancer Drug Revenue by Type (2024-2034) & (US$ Million)
Table 95. APAC Anti-Cancer Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 96. APAC Anti-Cancer Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 97. APAC Anti-Cancer Drug Revenue by Application (2018-2023) & (US$ Million)
Table 98. APAC Anti-Cancer Drug Revenue by Application (2024-2034) & (US$ Million)
Table 99. APAC Anti-Cancer Drug Revenue by Region: 2018 VS 2024 VS 2034 (US$ Million)
Table 100. APAC Anti-Cancer Drug Revenue by Region (2018-2023) & (US$ Million)
Table 101. APAC Anti-Cancer Drug Revenue by Region (2024-2034) & (US$ Million)
Table 102. APAC Anti-Cancer Drug Sales Quantity by Region (2018-2023) & (K Units)
Table 103. APAC Anti-Cancer Drug Sales Quantity by Region (2024-2034) & (K Units)
Table 104. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Company (2018-2023) & (K Units)
Table 105. Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Company (2018-2023) & (US$ Million)
Table 106. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Type (2018-2023) & (K Units)
Table 107. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Type (2024-2034) & (K Units)
Table 108. Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Type (2018-2023) & (US$ Million)
Table 109. Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Type (2024-2034) & (US$ Million)
Table 110. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Application (2018-2023) & (K Units)
Table 111. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Application (2024-2034) & (K Units)
Table 112. Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Application (2018-2023) & (US$ Million)
Table 113. Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Application (2024-2034) & (US$ Million)
Table 114. Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Country: 2018 VS 2024 VS 2034 (US$ Million)
Table 115. Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Country (2018-2023) & (US$ Million)
Table 116. Middle East, Africa and Latin America Anti-Cancer Drug Revenue by Country (2024-2034) & (US$ Million)
Table 117. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Country (2018-2023) & (K Units)
Table 118. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity by Country (2024-2034) & (K Units)
Table 119. Merck Company Information
Table 120. Merck Description and Overview
Table 121. Merck Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 122. Merck Anti-Cancer Drug Product and Services
Table 123. Merck Anti-Cancer Drug SWOT Analysis
Table 124. Merck Recent Developments
Table 125. Bristol-Myers Squibb Company Information
Table 126. Bristol-Myers Squibb Description and Overview
Table 127. Bristol-Myers Squibb Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 128. Bristol-Myers Squibb Anti-Cancer Drug Product and Services
Table 129. Bristol-Myers Squibb Anti-Cancer Drug SWOT Analysis
Table 130. Bristol-Myers Squibb Recent Developments
Table 131. Bayer Company Information
Table 132. Bayer Description and Overview
Table 133. Bayer Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 134. Bayer Anti-Cancer Drug Product and Services
Table 135. Bayer Anti-Cancer Drug SWOT Analysis
Table 136. Bayer Recent Developments
Table 137. GlaxoSmithKline Company Information
Table 138. GlaxoSmithKline Description and Overview
Table 139. GlaxoSmithKline Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 140. GlaxoSmithKline Anti-Cancer Drug Product and Services
Table 141. GlaxoSmithKline Anti-Cancer Drug SWOT Analysis
Table 142. GlaxoSmithKline Recent Developments
Table 143. Novartis Company Information
Table 144. Novartis Description and Overview
Table 145. Novartis Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 146. Novartis Anti-Cancer Drug Product and Services
Table 147. Novartis Anti-Cancer Drug SWOT Analysis
Table 148. Novartis Recent Developments
Table 149. Sanofi Company Information
Table 150. Sanofi Description and Overview
Table 151. Sanofi Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 152. Sanofi Anti-Cancer Drug Product and Services
Table 153. Sanofi Anti-Cancer Drug SWOT Analysis
Table 154. Sanofi Recent Developments
Table 155. Pfizer Company Information
Table 156. Pfizer Description and Overview
Table 157. Pfizer Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 158. Pfizer Anti-Cancer Drug Product and Services
Table 159. Pfizer Anti-Cancer Drug SWOT Analysis
Table 160. Pfizer Recent Developments
Table 161. Amgen Company Information
Table 162. Amgen Description and Overview
Table 163. Amgen Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 164. Amgen Anti-Cancer Drug Product and Services
Table 165. Amgen Anti-Cancer Drug SWOT Analysis
Table 166. Amgen Recent Developments
Table 167. Celgene Corporation Company Information
Table 168. Celgene Corporation Description and Overview
Table 169. Celgene Corporation Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 170. Celgene Corporation Anti-Cancer Drug Product and Services
Table 171. Celgene Corporation Anti-Cancer Drug SWOT Analysis
Table 172. Celgene Corporation Recent Developments
Table 173. Ariad Pharmaceuticals Company Information
Table 174. Ariad Pharmaceuticals Description and Overview
Table 175. Ariad Pharmaceuticals Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 176. Ariad Pharmaceuticals Anti-Cancer Drug Product and Services
Table 177. Ariad Pharmaceuticals Anti-Cancer Drug SWOT Analysis
Table 178. Ariad Pharmaceuticals Recent Developments
Table 179. Eli Lilly Company Information
Table 180. Eli Lilly Description and Overview
Table 181. Eli Lilly Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 182. Eli Lilly Anti-Cancer Drug Product and Services
Table 183. Eli Lilly Recent Developments
Table 184. Hoffmann-La Roche Ltd. Company Information
Table 185. Hoffmann-La Roche Ltd. Description and Overview
Table 186. Hoffmann-La Roche Ltd. Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 187. Hoffmann-La Roche Ltd. Anti-Cancer Drug Product and Services
Table 188. Hoffmann-La Roche Ltd. Recent Developments
Table 189. AstraZeneca Company Information
Table 190. AstraZeneca Description and Overview
Table 191. AstraZeneca Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 192. AstraZeneca Anti-Cancer Drug Product and Services
Table 193. AstraZeneca Recent Developments
Table 194. Boehringer Ingelheim GmbH Company Information
Table 195. Boehringer Ingelheim GmbH Description and Overview
Table 196. Boehringer Ingelheim GmbH Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 197. Boehringer Ingelheim GmbH Anti-Cancer Drug Product and Services
Table 198. Boehringer Ingelheim GmbH Recent Developments
Table 199. Teva Pharmaceuticals Company Information
Table 200. Teva Pharmaceuticals Description and Overview
Table 201. Teva Pharmaceuticals Anti-Cancer Drug Sales Quantity (K Units), Revenue (US$ Million), Average Selling Price (ASP) (USD/Unit) and Gross Margin (2018-2023)
Table 202. Teva Pharmaceuticals Anti-Cancer Drug Product and Services
Table 203. Teva Pharmaceuticals Recent Developments
Table 204. Key Raw Materials Lists
Table 205. Raw Materials Key Suppliers Lists
Table 206. Anti-Cancer Drug Distributors List
Table 207. Anti-Cancer Drug Customers List
Table 208. Anti-Cancer Drug Market Trends
Table 209. Anti-Cancer Drug Market Drivers
Table 210. Anti-Cancer Drug Market Challenges
Table 211. Anti-Cancer Drug Market Restraints
Table 212. Research Programs/Design for This Report
Table 213. Key Data Information from Secondary Sources
Table 214. Key Data Information from Primary Sources
List of Figures
Figure 1. Anti-Cancer Drug Product Picture
Figure 2. Global Anti-Cancer Drug Market Size Growth Rate by Type, 2018 VS 2024 VS 2034 (US$ Million)
Figure 3. Global Anti-Cancer Drug Market Share by Type in 2024 & 2034
Figure 4. Avastin Product Picture
Figure 5. Rituxan Product Picture
Figure 6. Herceptin Product Picture
Figure 7. Alimta Product Picture
Figure 8. Global Anti-Cancer Drug Market Size Growth Rate by Application, 2018 VS 2024 VS 2034 (US$ Million)
Figure 9. Global Anti-Cancer Drug Market Share by Application in 2024 & 2034
Figure 10. Hospital
Figure 11. Clinic
Figure 12. Home Care
Figure 13. Anti-Cancer Drug Report Years Considered
Figure 14. Global Anti-Cancer Drug Revenue, (US$ Million), 2018 VS 2024 VS 2034
Figure 15. Global Anti-Cancer Drug Revenue 2018-2034 (US$ Million)
Figure 16. Global Anti-Cancer Drug Revenue Market Share by Region in Percentage: 2024 Versus 2034
Figure 17. Global Anti-Cancer Drug Sales Quantity 2018-2034 (K Units)
Figure 18. Global Anti-Cancer Drug Sales Quantity Market Share by Region (2018-2023)
Figure 19. Global Anti-Cancer Drug Sales Quantity Market Share by Region (2024-2034)
Figure 20. North America Anti-Cancer Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 21. North America Anti-Cancer Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 22. Europe Anti-Cancer Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 23. Europe Anti-Cancer Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 24. China Anti-Cancer Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 25. China Anti-Cancer Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 26. APAC Anti-Cancer Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 27. APAC Anti-Cancer Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 28. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity YoY (2018-2034) & (K Units)
Figure 29. Middle East, Africa and Latin America Anti-Cancer Drug Revenue YoY (2018-2034) & (US$ Million)
Figure 30. The Top 10 and Top 5 Players Market Share by Anti-Cancer Drug Sales Quantity in 2024
Figure 31. The Top 10 and Top 5 Players Market Share by Anti-Cancer Drug Revenue in 2024
Figure 32. Anti-Cancer Drug Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2018 VS 2024
Figure 33. Global Anti-Cancer Drug Sales Quantity Market Share by Type (2018-2034)
Figure 34. Global Anti-Cancer Drug Revenue Market Share by Type (2018-2034)
Figure 35. Global Anti-Cancer Drug Sales Quantity Market Share by Application (2018-2034)
Figure 36. Global Anti-Cancer Drug Revenue Market Share by Application (2018-2034)
Figure 37. North America Anti-Cancer Drug Revenue Market Share by Company in 2024
Figure 38. North America Anti-Cancer Drug Sales Quantity Market Share by Company in 2024
Figure 39. North America Anti-Cancer Drug Sales Quantity Market Share by Type (2018-2034)
Figure 40. North America Anti-Cancer Drug Revenue Market Share by Type (2018-2034)
Figure 41. North America Anti-Cancer Drug Sales Quantity Market Share by Application (2018-2034)
Figure 42. North America Anti-Cancer Drug Revenue Market Share by Application (2018-2034)
Figure 43. North America Anti-Cancer Drug Revenue Share by Country (2018-2034)
Figure 44. North America Anti-Cancer Drug Sales Quantity Share by Country (2018-2034)
Figure 45. U.S. Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 46. Canada Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 47. Europe Anti-Cancer Drug Sales Quantity Market Share by Company in 2024
Figure 48. Europe Anti-Cancer Drug Revenue Market Share by Company in 2024
Figure 49. Europe Anti-Cancer Drug Sales Quantity Market Share by Type (2018-2034)
Figure 50. Europe Anti-Cancer Drug Revenue Market Share by Type (2018-2034)
Figure 51. Europe Anti-Cancer Drug Sales Quantity Market Share by Application (2018-2034)
Figure 52. Europe Anti-Cancer Drug Revenue Market Share by Application (2018-2034)
Figure 53. Europe Anti-Cancer Drug Revenue Share by Country (2018-2034)
Figure 54. Europe Anti-Cancer Drug Sales Quantity Share by Country (2018-2034)
Figure 55. Germany Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 56. France Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 57. U.K. Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 58. Italy Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 59. Russia Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 60. China Anti-Cancer Drug Sales Quantity Market Share by Company in 2024
Figure 61. China Anti-Cancer Drug Revenue Market Share by Company in 2024
Figure 62. China Anti-Cancer Drug Sales Quantity Market Share by Type (2018-2034)
Figure 63. China Anti-Cancer Drug Revenue Market Share by Type (2018-2034)
Figure 64. China Anti-Cancer Drug Sales Quantity Market Share by Application (2018-2034)
Figure 65. China Anti-Cancer Drug Revenue Market Share by Application (2018-2034)
Figure 66. APAC Anti-Cancer Drug Sales Quantity Market Share by Company in 2024
Figure 67. APAC Anti-Cancer Drug Revenue Market Share by Company in 2024
Figure 68. APAC Anti-Cancer Drug Sales Quantity Market Share by Type (2018-2034)
Figure 69. APAC Anti-Cancer Drug Revenue Market Share by Type (2018-2034)
Figure 70. APAC Anti-Cancer Drug Sales Quantity Market Share by Application (2018-2034)
Figure 71. APAC Anti-Cancer Drug Revenue Market Share by Application (2018-2034)
Figure 72. APAC Anti-Cancer Drug Revenue Share by Region (2018-2034)
Figure 73. APAC Anti-Cancer Drug Sales Quantity Share by Region (2018-2034)
Figure 74. Japan Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 75. South Korea Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 76. China Taiwan Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 77. Southeast Asia Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 78. India Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 79. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity Market Share by Company in 2024
Figure 80. Middle East, Africa and Latin America Anti-Cancer Drug Revenue Market Share by Company in 2024
Figure 81. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity Market Share by Type (2018-2034)
Figure 82. Middle East, Africa and Latin America Anti-Cancer Drug Revenue Market Share by Type (2018-2034)
Figure 83. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity Market Share by Application (2018-2034)
Figure 84. Middle East, Africa and Latin America Anti-Cancer Drug Revenue Market Share by Application (2018-2034)
Figure 85. Middle East, Africa and Latin America Anti-Cancer Drug Sales Quantity Share by Country (2018-2034)
Figure 86. Middle East, Africa and Latin America Anti-Cancer Drug Revenue Share by Country (2018-2034)
Figure 87. Brazil Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 88. Mexico Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 89. Turkey Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 90. Israel Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 91. GCC Countries Anti-Cancer Drug Revenue (2018-2034) & (US$ Million)
Figure 92. Anti-Cancer Drug Value Chain
Figure 93. Anti-Cancer Drug Production Process
Figure 94. Channels of Distribution (Direct Vs Distribution)
Figure 95. Distributors Profiles
Figure 96. Bottom-up and Top-down Approaches for This Report
Figure 97. Data Triangulation
Figure 98. Key Executives Interviewed